Natural antibodies (Abs) can target host glycans on the surface of pathogens. We studied the evolution of glycan-reactive B cells of rhesus macaques and humans using glycosylated HIV-1 envelope (Env) as a model antigen. 2G12 is a broadly neutralizing Ab (bnAb) that targets a conserved glycan patch on Env of geographically diverse HIV-1 strains using a unique heavy-chain (VH) domain-swapped architecture that results in fragment antigen-binding (Fab) dimerization. Here, we describe HIV-1 Env Fab-dimerized glycan (FDG)-reactive bnAbs without VH-swapped domains from simian-human immunodeficiency virus (SHIV)-infected macaques. FDG Abs also recognized cell-surface glycans on diverse pathogens, including yeast and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike. FDG precursors were expanded by glycan-bearing immunogens in macaques and were abundant in HIV-1-naive humans. Moreover, FDG precursors were predominately mutated IgM+IgD+CD27+, thus suggesting that they originated from a pool of antigen-experienced IgM+ or marginal zone B cells.

• MeSH
• B-lymfocyty imunologie   MeSH
• COVID-19 imunologie   MeSH
• dimerizace MeSH
• epitopy imunologie   MeSH
• genové produkty env - virus lidské imunodeficience chemie   genetika   imunologie   MeSH
• glykoprotein S, koronavirus imunologie   MeSH
• glykosylace MeSH
• HIV infekce imunologie   MeSH
• HIV protilátky imunologie   MeSH
• HIV-1 imunologie   MeSH
• imunoglobuliny - Fab fragmenty chemie   imunologie   MeSH
• lidé MeSH
• Macaca mulatta MeSH
• neutralizující protilátky imunologie   MeSH
• polysacharidy chemie   imunologie   MeSH
• receptory antigenů B-buněk chemie   MeSH
• SARS-CoV-2 imunologie   MeSH
• široce neutralizující protilátky imunologie   MeSH
• vakcíny imunologie   MeSH
• virus opičí imunodeficience genetika   imunologie   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Research Support, N.I.H., Extramural MeSH

Palliative care including hospice care is appropriate for advanced dementia, but policy initiatives and implementation have lagged, while treatment may vary. We compare care for people with advanced dementia in the United States (US), The Netherlands, and Israel. We conducted a narrative literature review and expert physician consultation around a case scenario focusing on three domains in the care of people with advanced dementia: (1) place of residence, (2) access to palliative care, and (3) treatment. We found that most people with advanced dementia live in nursing homes in the US and The Netherlands, and in the community in Israel. Access to specialist palliative and hospice care is improving in the US but is limited in The Netherlands and Israel. The two data sources consistently showed that treatment varies considerably between countries with, for example, artificial nutrition and hydration differing by state in the US, strongly discouraged in The Netherlands, and widely used in Israel. We conclude that care in each country has positive elements: hospice availability in the US, the general palliative approach in The Netherlands, and home care in Israel. National Dementia Plans should include policy regarding palliative care, and public and professional awareness must be increased.

• Publikační typ
• časopisecké články MeSH